盐酸卡普托胺 | 904-04-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 盐酸卡普托胺
• 英文名称: captodiame hydrochloride
• 英文别名: [2-(4-butylsulfanyl-benzhydrylmercapto)-ethyl]-dimethyl-amine; hydrochloride；[2-(4-Butylmercapto-benzhydrylmercapto)-aethyl]-dimethyl-amin; Hydrochlorid；2-[(4-butylsulfanylphenyl)-phenylmethyl]sulfanyl-N,N-dimethylethanamine;hydrochloride
• CAS: 904-04-1
• 化学式: C₂₁H₂₉NS₂*ClH
• 分子量: 396.061
• InChiKey: IQCZDPRPOLRNQX-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132°

计算性质

• 辛醇/水分配系数(LogP)：
  1.55
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pharmaceutical compositions for prevention of overdose or abuse
  申请人：Mickle Travis

  公开号：US20060014697A1

  公开（公告）日：2006-01-19

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及制药组合物，其中化学基团连接到活性剂上，以大大降低活性剂引起过量或被滥用的潜力。当以适当剂量给予时，该制药组合物提供与母体活性剂类似的治疗活性。
• PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE
  申请人：MICKLE TRAVIS

  公开号：US20110046226A1

  公开（公告）日：2011-02-24

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及药物组合物，其中化学基团与活性成分以一种方式连接，从而大大降低了活性成分引起过量或被滥用的潜力。当以适当剂量给药时，该药物组合物提供与原始活性成分类似的治疗活性。
• Pharmaceutical preparations based on active ingredients susceptible to illict administration
  申请人：ALTERGON S.A.

  公开号：EP1273301A2

  公开（公告）日：2003-01-08

  The present invention provides oral pharmaceutical preparations unsuitable for illicit administration to victims.

  本发明提供了不适合非法给受害者服用的口服药物制剂。
• Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
  申请人：NICOX OPHTHALMICS, INC.

  公开号：US10174071B2

  公开（公告）日：2019-01-08

  The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).

  本发明进一步提供了制备疏水性治疗剂（如氟替卡松或曲安西龙）纳米晶体的方法、其药物组合物（如局部或鼻内组合物）以及治疗和/或预防诸如睑缘炎、睑板腺功能障碍或皮肤炎症或呼吸系统疾病（如哮喘）等疾病的症状和/或体征的方法。
• Methods of treating Prader-Willi syndrome
  申请人：Ovid Therapeutics Inc.

  公开号：US10195165B2

  公开（公告）日：2019-02-05

  Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R, R′, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.

  提供了治疗需要治疗的受试者的普拉德-威利综合征的方法。这些方法包括向受试者施用有效量的式Ⅰ化合物、 或其药学上可接受的盐，其中 R、R′、X、Y 和 Z 的定义如说明书所述。在实施方案中，向受试者施用有效量的卡托二胺或其药学上可接受的盐。